Head to Head Contrast: Milestone Scientific (NYSE:MLSS) & ResMed (NYSE:RMD)

Milestone Scientific (NYSE:MLSS) and ResMed (NYSE:RMD) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Valuation and Earnings

This table compares Milestone Scientific and ResMed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Scientific	$9.42 million	4.27	-$6.93 million	($0.04)	-11.10
ResMed	$5.65 billion	5.57	$1.52 billion	$10.43	20.93

ResMed has higher revenue and earnings than Milestone Scientific. Milestone Scientific is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Milestone Scientific and ResMed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Scientific	0	0	1	0	3.00
ResMed	0	10	6	0	2.38

Milestone Scientific presently has a consensus target price of $1.00, suggesting a potential upside of 125.23%. ResMed has a consensus target price of $240.31, suggesting a potential upside of 10.09%. Given Milestone Scientific’s stronger consensus rating and higher possible upside, research analysts plainly believe Milestone Scientific is more favorable than ResMed.

Volatility and Risk

Milestone Scientific has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Institutional & Insider Ownership

5.8% of Milestone Scientific shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 9.2% of Milestone Scientific shares are owned by company insiders. Comparatively, 0.7% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Milestone Scientific and ResMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Milestone Scientific	-52.01%	-60.26%	-40.23%
ResMed	26.94%	25.58%	18.89%

Summary

ResMed beats Milestone Scientific on 10 of the 14 factors compared between the two stocks.

About Milestone Scientific

Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.

About ResMed

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN’s software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.